October 16, 2017 FIRST PUBLICATION FROM BARRICAID LEVEL-1 RCT OUT
On August 28 the Journal of Pain Research (Journal Impact Factor 2.581) reported that placement of a bone-anchored anular closure device (ACD) following lumbar discectomy significantly reduces reoperation risk within 90 days of discharge.
May 30, 2017 Intrinsic proud sponsor of 44th ISSLS annual meeting
Over 500 lead spine clinicians and scientists gathered in Athens from May 29th – June 2nd, to present and listen to recent scientific findings at the 44th Annual Meeting of the International Society for the Study of the Lumbar Spine.
90-day readmission and reoperation rates comparing Barricaid® versus discectomy alone were discussed in two podium presentations, showing substantial reductions in favor of Barricaid.
A comparison of prospectively collected large defect discectomy data to the literature showed that 5.0% of large defect patients (RCT) underwent reoperations at index level within 90-days of surgery, compared to a 2.1% weighted average rate in the general population (Literature).
The topic of Anular Closure has been given significant ‘air time’ at Australia’s largest spine conference.
December 01, 2016 Germany Spine Society Conference: Superiority all-around!
The annual meeting of the German Spine Society (DWG) took place in Hannover, 1-3 December, coinciding with the study completion of Barricaid’s level 1 Superiority RCT.
Intrinsic again was a proud sponsor of the 67th Annual Meeting of the German Society of Neurosurgery in Frankfurt, Germany (12 - 15 June).
April 22, 2016 Intrinsic introduces strategic partnership with RealSpine
Intrinsic has invested time and resource to deliver our customers convenient, safe and re-producible training in a manner that is both efficient and effective.
The 27th annual meeting of the Spine Society of Australia included 3 podium presentations associated with Barricaid® Anular Closure.
Study investigates the impact of opening the annulus on intradiscal pressure and whether implantation of an annular closure device (ACD) can restore physiologic pressures.
The Lighthouse registry initiative is part of Intrinsic's stepwise, evidence-based introduction of the Barricaid® Anular Closure treatment.
September 30, 2015 US Surgeon survey confirms need for anular closure
Learn what the independent survery among US surgeons told us about the need for anular closure.
On Saturday 19 September, Barricaid® Anular Closure received its first comprehensive introduction on U.S. soil.
This year's BioSpine featured a first-time dedicated scientific session on the “Treatment of Anulus Fibrosus Defects”.
Strong faculty of leading international experts provided a 360° perspective on the clinical and economic need, patient selection, and interim safety analysis of Barricaid® Anular Closure.
Learn more about effect of anular closure on disc height maintenance and reoperated recurrent herniation following lumbar discectomy.
February 01, 2015 Barricaid featured at Orthopaedic Research Course AFOR
Intrinsic was extremely pleased to see that Barricaid® was discussed in a lecture by Prof. Christoph Josten, immediate Past President of the German Spine Society.
September 20, 2011 Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President and CEO
February 17, 2011 Intrinsic Enrolls First Patient in Barricaid Trial